4547 Stock Overview
Researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Kissei Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥3,445.00 |
| 52 Week High | JP¥3,910.00 |
| 52 Week Low | JP¥3,000.00 |
| Beta | -0.014 |
| 1 Month Change | -6.64% |
| 3 Month Change | -1.29% |
| 1 Year Change | 6.99% |
| 3 Year Change | 51.23% |
| 5 Year Change | 8.16% |
| Change since IPO | 63.18% |
Recent News & Updates
Kissei Pharmaceutical (TSE:4547) Will Pay A Dividend Of ¥45.00
Dec 18
Kissei Pharmaceutical (TSE:4547) Will Pay A Dividend Of ¥45.00
Dec 04Weak Statutory Earnings May Not Tell The Whole Story For Kissei Pharmaceutical (TSE:4547)
Nov 27Recent updates
Kissei Pharmaceutical (TSE:4547) Will Pay A Dividend Of ¥45.00
Dec 18Kissei Pharmaceutical (TSE:4547) Will Pay A Dividend Of ¥45.00
Dec 04Weak Statutory Earnings May Not Tell The Whole Story For Kissei Pharmaceutical (TSE:4547)
Nov 27Kissei Pharmaceutical (TSE:4547) Will Pay A Larger Dividend Than Last Year At ¥45.00
Sep 24Kissei Pharmaceutical (TSE:4547) Is Increasing Its Dividend To ¥45.00
Sep 09Kissei Pharmaceutical's (TSE:4547) Dividend Will Be Increased To ¥45.00
Jul 25Kissei Pharmaceutical (TSE:4547) Will Pay A Larger Dividend Than Last Year At ¥45.00
Jul 11Kissei Pharmaceutical's (TSE:4547) Shareholders May Want To Dig Deeper Than Statutory Profit
May 21Kissei Pharmaceutical Co., Ltd. (TSE:4547) Yearly Results: Here's What Analysts Are Forecasting For This Year
May 09Kissei Pharmaceutical (TSE:4547) Is Due To Pay A Dividend Of ¥41.00
Mar 27Kissei Pharmaceutical (TSE:4547) Is Due To Pay A Dividend Of ¥41.00
Mar 13Kissei Pharmaceutical (TSE:4547) Has Announced A Dividend Of ¥41.00
Feb 27Shareholder Returns
| 4547 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -2.8% | -0.1% | -1.5% |
| 1Y | 7.0% | 10.6% | 13.7% |
Return vs Industry: 4547 underperformed the JP Pharmaceuticals industry which returned 10.6% over the past year.
Return vs Market: 4547 underperformed the JP Market which returned 13.7% over the past year.
Price Volatility
| 4547 volatility | |
|---|---|
| 4547 Average Weekly Movement | 2.7% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in JP Market | 7.3% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 4547 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4547's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 1,779 | Mutsuo Kanzawa | www.kissei.co.jp |
Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Kalogra tablets, for the treatment of ulcerative colitis; Tabuneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Minirin Melt OD tablets; Malizeb tablets; Tavaris tablets for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of renal anemia. Its products in pipeline include CG0070, which is in Phase III clinical trial to treat non-muscle-invasive bladder cancer; Linzagolix, which is in Phase III clinical trial for the treatment of uterine fibroids and endometriosis; KDT-3594, which is in Phase II clinical trial to treat Parkinson's disease; KSP-0243 that is in Phase II clinical trial to treat Ulcerative colitis; and Difelikefalin, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients.
Kissei Pharmaceutical Co., Ltd. Fundamentals Summary
| 4547 fundamental statistics | |
|---|---|
| Market cap | JP¥147.46b |
| Earnings (TTM) | JP¥10.73b |
| Revenue (TTM) | JP¥81.07b |
13.7x
P/E Ratio1.8x
P/S RatioIs 4547 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4547 income statement (TTM) | |
|---|---|
| Revenue | JP¥81.07b |
| Cost of Revenue | JP¥40.63b |
| Gross Profit | JP¥40.44b |
| Other Expenses | JP¥29.71b |
| Earnings | JP¥10.73b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 03, 2025
| Earnings per share (EPS) | 250.69 |
| Gross Margin | 49.88% |
| Net Profit Margin | 13.24% |
| Debt/Equity Ratio | 0.6% |
How did 4547 perform over the long term?
See historical performance and comparisonDividends
2.6%
Current Dividend Yield17%
Payout RatioDoes 4547 pay a reliable dividends?
See 4547 dividend history and benchmarks| Kissei Pharmaceutical dividend dates | |
|---|---|
| Ex Dividend Date | Mar 28 2025 |
| Dividend Pay Date | Jun 26 2025 |
| Days until Ex dividend | 96 days |
| Days until Dividend pay date | 186 days |
Does 4547 pay a reliable dividends?
See 4547 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 20:53 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kissei Pharmaceutical Co., Ltd. is covered by 16 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ritsuo Watanabe | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Global Markets Japan Inc. |
| Hidemaru Yamaguchi | Citigroup Inc |